Article Sidebar

pdf
Date Published: 18/09/2023
Abstract Views: 606
Views pdf: 289
DOI: https://doi.org/10.51298/vmj.v530i1.6637
Issue
Vol. 530 No. 1 (2023)
Section
Các bài báo
How to Cite
Hoàng, T. N. V., Trần, T. N. V., & Bùi, T. T. Q. (2023). EFFICACY, EFFECTIVENESS, AND SAFETY OF DAPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE MANAGEMENT: A SYSTEMATIC REVIEW. Vietnam Medical Journal, 530(1). https://doi.org/10.51298/vmj.v530i1.6637

EFFICACY, EFFECTIVENESS, AND SAFETY OF DAPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE MANAGEMENT: A SYSTEMATIC REVIEW

Thy Nhạc Vũ Hoàng1,, Thị Ngọc Vân Trần1, Thị Thu Quỳnh Bùi2
1 University of Medicine and Pharmacy at Ho Chi Minh City
2 AstraZeneca Vietnam

Main Article Content

Abstract

Objectives: This systematic review aimed to evaluate the efficacy, effectiveness, and safety of dapagliflozin in the management of chronic kidney disease (CKD). Methods: A comprehensive search strategy was employed to identify relevant studies published on PubMed, Embase, and Cochrane as of December 21, 2022. The efficacy and effectiveness outcomes evaluated were composite cardiorenal outcomes, renal outcomes, cardiovascular outcomes, and all-cause mortality. Safety was assessed by comparing the frequency of adverse events. Results: The review identified 8 studies that demonstrated the efficacy and effectiveness of dapagliflozin in improving cardiorenal outcomes, renal outcomes, cardiovascular outcomes, and all-cause mortality in CKD patients at different stages, with or without diabetes type 2, heart failure, or atherosclerotic cardiovascular disease. The frequency of adverse events was comparable between groups, and there were no statistically significant differences between geographic regions (p>0.05). Conclusion: The results suggest that dapagliflozin is a safe and effective treatment option for the management of CKD, improving renal and cardiovascular outcomes and reducing mortality.

Article Details

Keywords

dapagliflozin, chronic kidney disease, efficacy, effectiveness, safety, systematic review.

References

1. Vart P, Correa-Rotter R, Hou FF, Jongs N, Chertow GM, Langkilde AM, et al. Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. Kidney Int Rep. 2022;7(4):699-707. Epub 2022/05/03. doi: 10.1016/j.ekir.2022.01.1060. PubMed PMID: 35497805; PubMed Central PMCID: PMCPMC9039473.
2. Mosenzon O, Raz I, Wiviott SD, Schechter M, Goodrich EL, Yanuv I, et al. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Diabetes care. 2022;45(10):2350-9. Epub 2022/08/24. doi: 10.2337/dc22-0382. PubMed PMID: 35997319.
3. Heerspink HJLK, A. Thuresson, M. Melzer-Cohen, C. Chodick, G. Khunti, K. Wilding, J. P. H. Garcia Rodriguez, L. A. Cea-Soriano, L. Kohsaka, S. Nicolucci, A. Lucisano, G. Lin, F. J. Wang, C. Y. Wittbrodt, E. Fenici, P. Kosiborod, M. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. The lancet Diabetes & endocrinology. 2020; 8(1):27-35. Epub 2019/12/22. doi: 10.1016/ s2213-8587(19)30384-5. PubMed PMID: 31862149.
4. Cherney DZID, C. C. J. Barbour, S. J. Cattran, D. Abdul Gafor, A. H. Greasley, P. J. Laverman, G. D. Lim, S. K. Di Tanna, G. L. Reich, H. N. Vervloet, M. G. Wong, M. G. Gansevoort, R. T. Heerspink, H. J. L. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. The lancet Diabetes & endocrinology. 2020;8(7):582-93. Epub 2020/06/20. doi: 10.1016/s2213-8587(20)30162-5. PubMed PMID: 32559474.
5. Pollock CS, B. Reyner, D. Rossing, P. Sjöström, C. D. Wheeler, D. C. Langkilde, A. M. Heerspink, H. J. L. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. The lancet Diabetes & endocrinology. 2019;7(6):429-41. Epub 2019/04/18. doi: 10.1016/s2213-8587(19)30086-5. PubMed PMID: 30992195.
6. Fioretto PDP, S. Buse, J. B. Goldenberg, R. Giorgino, F. Reyner, D. Langkilde, A. M. Sjöström, C. D. Sartipy, P. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes, obesity & metabolism. 2018;20(11):2532-40. Epub 2018/06/12. doi: 10.1111/dom.13413. PubMed PMID: 29888547; PubMed Central PMCID: PMCPMC6175614.
7. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney international. 2014;85(4):962-71. Epub 2013/09/27. doi: 10.1038/ki.2013.356. PubMed PMID: 24067431; PubMed Central PMCID: PMCPMC3973038.
8. Jhund PSS, S. D. Docherty, K. F. Heerspink, H. J. L. Anand, I. S. Böhm, M. Chopra, V. de Boer, R. A. Desai, A. S. Ge, J. Kitakaze, M. Merkley, B. O'Meara, E. Shou, M. Tereshchenko, S. Verma, S. Vinh, P. N. Inzucchi, S. E. Køber, L. Kosiborod, M. N. Martinez, F. A. Ponikowski, P. Sabatine, M. S. Bengtsson, O. Langkilde, A. M. Sjöstrand, M. McMurray, J. J. V. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation. 2021;143(4):298-309. Epub 2020/10/13. doi: 10.1161/circulationaha.120.050391. PubMed PMID: 33040613; PubMed Central PMCID: PMCPMC7834909.